First two-drug pill approved for new HIV treatment starters

Treatment- naïve people living with HIV now have drug-sparing antiretroviral treatment options with new once-daily, two-drug, fixed-dose treatment, Dovato.

Read More

Activists file post grant opposition to challenge a patent prevents purchase of cheaper treatment for hepatitis C

In GTPI’s opinion, this concession is undeserved. The main argument is that the patent
lacks sufficiency disclosure, ie, it does not have the level of detail necessary for the
technology described therein to be reproduced by a person skilled in the art. This is
fundamental to justify the granting of the patent.

Read More

Benefits of landmark HIV drug outweigh risks of birth defects, study shows

The antiretroviral drug dolutegravir, taken in conjunction with other drugs to suppress an HIV patient’s viral load and to stop them passing the virus to others, is considered one of the best HIV drugs available and has become the cornerstone of treatment in many richer countries since it was first introduced in the United States in 2013.

Read More

An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions

Thomas Folks spent years in his U.S. Centers for Disease Control and Prevention lab developing a treatment to block deadly HIV in monkeys. Then San Francisco AIDS researcher Robert Grant, using $50 million in federal grants, proved the treatment worked in people who engaged in risky sex.

Read More


Publications


Infographic

AIDS in the world

AIDS in the world

See the trajectory
of the AIDS epidemic.

Newsletter

Newsletter

Your Name (required):


Your Email (required)

Please fill all widget settings!

Facebook